Cencora (NYSE:COR) Reaches New 1-Year High After Better-Than-Expected Earnings

Cencora, Inc. (NYSE:COR) hit a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $361.38 and last traded at $347.3020, with a volume of 292714 shares trading hands. The stock had previously closed at $344.53.

The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the company posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS.

Analyst Ratings Changes

COR has been the subject of a number of research analyst reports. Wells Fargo & Company raised their price target on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. UBS Group increased their price objective on shares of Cencora from $350.00 to $380.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Evercore ISI set a $340.00 price objective on shares of Cencora in a research note on Wednesday, October 8th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $329.55.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 41,544 shares of company stock worth $12,230,941. Insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

Institutional investors and hedge funds have recently bought and sold shares of the business. Atlantic Edge Private Wealth Management LLC raised its stake in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares during the period. Cornerstone Planning Group LLC raised its stake in shares of Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock valued at $26,000 after acquiring an additional 48 shares during the period. Costello Asset Management INC purchased a new stake in shares of Cencora in the 1st quarter valued at approximately $28,000. Vermillion & White Wealth Management Group LLC increased its stake in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after buying an additional 43 shares during the period. Finally, Cloud Capital Management LLC purchased a new stake in Cencora during the 3rd quarter worth approximately $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

The firm’s 50 day moving average is $310.25 and its two-hundred day moving average is $297.98. The stock has a market capitalization of $67.49 billion, a PE ratio of 35.93, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.